FairGlucose: A CGM Fairness Benchmark Reveals Subgroup Disparities Hidden in Population-Level Validation

Research on CGM-based AI tools highlights a critical issue where population-level accuracy metrics can mask significant performance disparities across diverse patient subgroups. A new benchmark, FairGlucose, demonstrated that while aggregate external validation appears stable, specific demographic strata experience notable variations in forecasting accuracy, particularly for Type 1 diabetes patients.

Why it matters

This research underscores the critical need for AI model validation to move beyond aggregate metrics, particularly in sensitive applications like healthcare. Failing to identify and address subgroup disparities in AI performance poses significant ethical, operational, and regulatory risks, potentially leading to inequitable outcomes and erosion of trust in AI-driven solutions.

Key insights

• Accuracy of CGM-based AI tools across patient demographics is insufficiently tested prior to clinical deployment.
• FairGlucose, a 300-patient CGM cohort balanced across 12 demographic strata, was constructed for evaluation.
• The cohort includes 132,480 forecasting samples and 3,945 unique behavioral events.
• Benchmarking 33 models across four families for 2-hour glucose forecasting revealed issues.
• Population-level external validation can conceal substantial subgroup disparities in AI model performance.
• Aggregate out-of-distribution metrics appear stable, but subgroup-level ratios range from 0.8 to 1.4.
• Type 1 diabetes patients show significant accuracy differences, specifically 6 mg/dL higher error rates.

Source

arXiv — Computers and Society — https://arxiv.org/abs/2608.18296